Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PIK3C2B | O00750 | 4/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742240 | 1.00 | KMT2A (1.00) | KMT2APOLBALDH1A1TDP1PIK3C2B | |
| SCHEMBL5740340 | 0.95 | KMT2A (0.91) | KMT2APOLBALDH1A1TDP1PIK3C2B | |
| SCHEMBL5740339 | 0.84 | KMT2A (0.72) | KMT2APOLBALDH1A1TDP1GAA | |
| SCHEMBL11557413 | 0.81 | KMT2A (0.68) | KMT2APOLBALDH1A1GAAMEN1 | |
| SCHEMBL11560068 | 0.81 | KMT2A (0.68) | KMT2APOLBALDH1A1 | |
| SCHEMBL11557639 | 0.81 | KMT2A (0.68) | KMT2APOLBALDH1A1GAAMEN1 | |
| SCHEMBL10650530 | 0.80 | KMT2A (0.67) | KMT2APOLBALDH1A1TDP1GAA | |
| SCHEMBL10644699 | 0.80 | KMT2A (0.67) | KMT2APOLBALDH1A1TDP1GAA | |
| SCHEMBL10798950 | 0.80 | KMT2A (0.67) | KMT2APOLBALDH1A1TDP1GAA | |
| SCHEMBL5740800 | 0.79 | KMT2A (0.66) | KMT2AALDH1A1TDP1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076928-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | ERISYON INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6974823-B2 | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same | GPI NIL HOLDINDGS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1244670-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL Holdings, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001046195-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL HOLDINGS, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | KMT2A 4086/4885POLB 2562/4885ALDH1A1 824/4885 |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | HNMT, HAAO, HTR3E | KMT2A 3409/4885POLB 3462/4885ALDH1A1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.